Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jul;38(4):306-315.
doi: 10.3343/alm.2018.38.4.306.

Galectin-3 Reflects the Echocardiographic Grades of Left Ventricular Diastolic Dysfunction

Uzair Ansari #  1 , Michael Behnes #  2 , Julia Hoffmann  2 , Michele Natale  2 , Christian Fastner  2 , Ibrahim El-Battrawy  2 , Jonas Rusnak  2 , Seung Hyun Kim  2 , Siegfried Lang  2 , Ursula Hoffmann  2 , Thomas Bertsch  3 , Martin Borggrefe  2 , Ibrahim Akin  2
Affiliations

Galectin-3 Reflects the Echocardiographic Grades of Left Ventricular Diastolic Dysfunction

Uzair Ansari et al. Ann Lab Med. 2018 Jul.

Abstract

Background: The level of Galectin-3 (Gal-3) protein purportedly reflects an ongoing cardiac fibrotic process and has been associated with ventricular remodeling, which is instrumental in the development of heart failure with preserved ejection fraction (HFpEF) syndrome. The aim of this study was to investigate the potential use of Gal-3 in improved characterization of the grades of diastolic dysfunction as defined by echocardiography.

Methods: Seventy HFpEF patients undergoing routine echocardiography were prospectively enrolled in the present monocentric study. Blood samples for measurements of Gal-3 and amino-terminal pro-brain natriuretic peptide (NT-proBNP) were collected within 24 hours pre- or post-echocardiographic examination. The classification of patients into subgroups based on diastolic dysfunction grade permitted detailed statistical analyses of the derived data.

Results: The Gal-3 serum levels of all patients corresponded to echocardiographic indices, suggesting HFpEF (E/A, P=0.03 and E/E', P=0.02). Gal-3 was also associated with progressive diastolic dysfunction, and increased levels corresponded to the course of disease (P=0.012). Detailed analyses of ROC curves suggested that Gal-3 levels could discriminate patients with grade III diastolic dysfunction (area under the curve [AUC]=0.770, P=0.005).

Conclusions: Gal-3 demonstrates remarkable effectiveness in the diagnosis of patients suffering from severe grade diastolic dysfunction. Increasing levels of Gal-3 possibly reflect the progressive course of HFpEF, as classified by the echocardiographic grades of diastolic dysfunction.

Keywords: Diastolic dysfunction; Galectin-3; NT-proBNP; Preserved ejection fraction.

PubMed Disclaimer

Conflict of interest statement

Thomas Bertsch performs reagent evaluation studies for Roche Diagnostics. All other authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1. Box plots showing increased levels of Galectin-3 (A) and increased levels of NT-proBNP (B) in patients with different grades of diastolic dysfunction. Significantly highest levels of Galectin-3 and NT-proBNP were noted in Grade III diastolic dysfunction, indicating a progressive increase in their levels along the course of the disease.
Abbreviation: NT-proBNP, amino-terminal pro-brain natriuretic peptide.
Fig. 2
Fig. 2. Receiver-operating characteristic (ROC) curve revealing an effective discrimination of patients with diastolic dysfunction III. ROC=diastolic dysfunction grade 3 curve. AUC–Area under the Curve.
Abbreviation: NT-proBNP, amino-terminal pro-brain natriuretic peptide.
See this image and copyright information in PMC

References

    1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation. 2014;129:e28–e292. - PMC - PubMed
    1. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787–1847. - PubMed
    1. Cheng JM, Akkerhuis KM, Battes LC, van Vark LC, Hillege HL, Paulus WJ, et al. Biomarkers of heart failure with normal ejection fraction: a systematic review. Eur J Heart Fail. 2013;15:1350–1362. - PubMed
    1. de Boer RA, Edelmann F, Cohen-Solal A, Mamas MA, Maisel A, Pieske B. Galectin-3 in heart failure with preserved ejection fraction. Eur J Heart Fail. 2013;15:1095–1101. - PubMed
    1. Tribouilloy C, Rusinaru D, Mahjoub H, Souliere V, Levy F, Peltier M, et al. Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study. Eur Heart J. 2008;29:339–347. - PubMed

LinkOut - more resources